# Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ADPT
## Company Profile
- Ticker: ADPT
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 25.39 USD
- Market cap: 2423072094.88 USD
- Last updated: 2026-08-11
## Business Overview
### Adaptive Immune-System Platform
Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics.
### Minimal Residual Disease
The company’s commercial MRD business is led by clonoSEQ, a sequencing-based test used to detect and monitor residual disease in blood cancers. Clinical testing and biopharmaceutical drug-development applications make MRD the company’s principal commercial engine.
### Immune Medicine
Adaptive also applies its platform to characterize immune responses and identify disease-specific immune signatures. This business supports biopharmaceutical partnerships and longer-term diagnostic and therapeutic opportunities in cancer and autoimmune disease.
## Why The Stock Is Moving

As of Aug 11, 2026, ADPT was little changed and closed at $25.39. No new same-company headline was identified in the current news window.

## Future Catalysts

- Adaptive still has a clean platform story in immune-system diagnostics and therapeutics, but the commercial side is where the company has to keep proving itself. The update is less about one binary event and more about whether the core immune products continue to move from scientific capability into routine clinical use.

## Recent News
- 2026-07-29 20:05 EST — [Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-reports-second-quarter-2026-financial-results-98b81673) — Source: Adaptive Biotechnologies
- 2026-07-09 20:05 EST — [Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-to-report-second-quarter-2026-financial-results-on-july-1166d6b4) — Source: Adaptive Biotechnologies
- 2026-06-30 12:30 EST — [Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial](https://biopharmsignal.com/news/ADPT/imviva-biotech-receives-fda-ide-authorization-for-clonoseq-assay-in-tenacity-01--1f1babe9) — Source: Adaptive Biotechnologies
- 2026-06-17 10:00 EST — [Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-corporation-prices-upsized-300-million-convertible-seni-92356ee8) — Source: Adaptive Biotechnologies
- 2026-06-15 20:10 EST — [Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-announces-plan-to-separate-its-mrd-and-immune-medicine--ef270574) — Source: Adaptive Biotechnologies